These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26253838)

  • 1. Nuclear Protein Phosphatase 1 α (PP1A) Expression is Associated with Poor Prognosis in p53 Expressing Glioblastomas.
    Shastry AH; Thota B; Srividya MR; Arivazhagan A; Santosh V
    Pathol Oncol Res; 2016 Apr; 22(2):287-92. PubMed ID: 26253838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
    Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
    Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glioblastoma-specific protein interaction network identifies PP1A and CSK21 as connecting molecules between cell cycle-associated genes.
    Ladha J; Donakonda S; Agrawal S; Thota B; Srividya MR; Sridevi S; Arivazhagan A; Thennarasu K; Balasubramaniam A; Chandramouli BA; Hegde AS; Kondaiah P; Somasundaram K; Santosh V; Rao SM
    Cancer Res; 2010 Aug; 70(16):6437-47. PubMed ID: 20663907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival.
    Chaurasia A; Park SH; Seo JW; Park CK
    J Korean Med Sci; 2016 Aug; 31(8):1208-14. PubMed ID: 27478330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P53 stratification reveals the prognostic utility of matrix metalloproteinase-9 protein expression in glioblastoma.
    Shastry AH; Thota B; Arimappamagan A; Santosh V
    Neurol India; 2015; 63(3):399-404. PubMed ID: 26053814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
    Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
    Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression and prognostic impact in glioblastoma.
    Nduom EK; Wei J; Yaghi NK; Huang N; Kong LY; Gabrusiewicz K; Ling X; Zhou S; Ivan C; Chen JQ; Burks JK; Fuller GN; Calin GA; Conrad CA; Creasy C; Ritthipichai K; Radvanyi L; Heimberger AB
    Neuro Oncol; 2016 Feb; 18(2):195-205. PubMed ID: 26323609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
    Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
    Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker.
    Harada K; Kurisu K; Tahara H; Tahara E; Ide T; Tahara E
    J Neurosurg; 2000 Oct; 93(4):618-25. PubMed ID: 11014540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
    Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
    PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy.
    Li S; Zhang W; Chen B; Jiang T; Wang Z
    Neurol Res; 2010 Sep; 32(7):690-4. PubMed ID: 19703338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. H3K27M, IDH1, and ATRX expression in pediatric GBM and their clinical and prognostic significance.
    Uppar AM; Sugur H; Prabhuraj AR; Rao MB; Devi BI; Sampath S; Arivazhagan A; Santosh V
    Childs Nerv Syst; 2019 Sep; 35(9):1537-1545. PubMed ID: 31152217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-κB nexus.
    Shukla S; Pia Patric IR; Thinagararjan S; Srinivasan S; Mondal B; Hegde AS; Chandramouli BA; Santosh V; Arivazhagan A; Somasundaram K
    Cancer Res; 2013 Nov; 73(22):6563-73. PubMed ID: 24078801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GBM-associated mutations and altered protein expression are more common in young patients.
    Ferguson SD; Xiu J; Weathers SP; Zhou S; Kesari S; Weiss SE; Verhaak RG; Hohl RJ; Barger GR; Reddy SK; Heimberger AB
    Oncotarget; 2016 Oct; 7(43):69466-69478. PubMed ID: 27579614
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Meel M; Jindal A; Kumar M; Mathur K; Singh A
    Asian J Neurosurg; 2024 Mar; 19(1):14-20. PubMed ID: 38751398
    [No Abstract]   [Full Text] [Related]  

  • 17. MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
    Kuan CT; Wakiya K; Herndon JE; Lipp ES; Pegram CN; Riggins GJ; Rasheed A; Szafranski SE; McLendon RE; Wikstrand CJ; Bigner DD
    BMC Cancer; 2010 Sep; 10():468. PubMed ID: 20809959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors.
    Burton EC; Lamborn KR; Forsyth P; Scott J; O'Campo J; Uyehara-Lock J; Prados M; Berger M; Passe S; Uhm J; O'Neill BP; Jenkins RB; Aldape KD
    Clin Cancer Res; 2002 Jan; 8(1):180-7. PubMed ID: 11801556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
    Ogura R; Tsukamoto Y; Natsumeda M; Isogawa M; Aoki H; Kobayashi T; Yoshida S; Okamoto K; Takahashi H; Fujii Y; Kakita A
    Neuropathology; 2015 Aug; 35(4):324-35. PubMed ID: 25950388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases.
    Korshunov A; Golanov A; Sycheva R; Pronin I
    J Clin Pathol; 1999 Aug; 52(8):574-80. PubMed ID: 10645226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.